行情

PALI

PALI

Palisade Bio Inc
NASDAQ

实时行情|Nasdaq Last Sale

1.190
+0.010
+0.84%
盘后: 1.190 0 0.00% 16:06 01/20 EST
开盘
1.180
昨收
1.190
最高
1.230
最低
1.180
成交量
2.86万
成交额
--
52周最高
16.02
52周最低
1.160
市值
1,615.31万
市盈率(TTM)
-0.2410
分时
5日
1月
3月
1年
5年
Stocks That Hit 52-Week Lows On Tuesday
  Tuesday morning saw 454 companies set new 52-week lows.
Benzinga · 2天前
从昨天开始的 61 个最大的推动者
Gainers Genprex, Inc. (NASDAQ: GNPX) shares surged 167.2% to settle at $3.50 on Monday. The FDA granted Fast Track Designation for Genprex’s lead drug candidate, Reqorsa Immunogene combination therapy.
Benzinga · 01/04 10:06
Palisade Bio to Present at the H.C. Wainwright BIOCONNECT Virtual Conference and Biotech Showcase
CARLSBAD, Calif., Dec. 29, 2021 (GLOBE NEWSWIRE) -- Palisade Bio, Inc. (Nasdaq: PALI), a clinical stage biopharmaceutical company advancing therapies for acute and chronic gastrointestinal (GI) complications, announces that they will present at the H.C. Wa...
GlobeNewswire · 2021/12/29 13:30
Palisade Bio stock up 5% on new U.S. patent for LB1148
Palisade Bio (NASDAQ:PALI) announces that the USPTO has granted a new patent for its lead investigational drug product, LB1148, for use in treating adhesions and postoperative ileus. Shares up 4.7% premarket at
Seekingalpha · 2021/12/08 14:00
Palisade Bio Reports Granted New US Patent Covering Protease Inhibitor LB1148 For Treating Adhesions, Postoperative Ileus
Issuance of Additional U.S. Patent No11,202,768 Further Bolsters Palisade Bio’s Patent Portfolio The Company Continues to Advance LB1148 for Key Indications After LB1148 Topline Efficacy Results from Phase 2 Trial
Benzinga · 2021/12/08 13:21
BRIEF-Palisade Bio Granted New U.S. Patent Covering Protease Inhibitor Lb1148 For Treating Adhesions And Postoperative Ileus
reuters.com · 2021/12/08 13:19
PTON, SBSW and ABUS among pre market gainers
CF Acquisition CFVIU +28% on deal to take conservative video platform Rumble public Phunware (NASDAQ:PHUN) +23%. Digital World Acquisition DWAC +23% on deal to take conservative video platform Rumble public Omeros OMER +18% to sell OMIDRIA
Seekingalpha · 2021/12/02 13:35
BRIEF-Palisade Bio Announces The European Patent Office To Grant Patent For Its Lead Drug Candidate LB1148, Providing Protection Through 2035
reuters.com · 2021/11/30 13:56
更多
财务预测
实际值(美元)
预测值(美元)
利润表更多
净利润(美元)
同比(%)
资产负债表更多
总资产(美元)
总负债(美元)
资产负债率(%)
现金流表更多
经营现金流(美元)
同比(%)
了解PALI最新的财务预测,通过PALI每股收益,每股净资产,每股现金流等数据分析Palisade Bio Inc近期的经营情况,然后做出明智的投资选择。
分析师评级

1位分析师的综合评级

买入

免责声明:分析师观点仅供投资者决策参考,不构成任何买卖投资建议。

0.00%强力推荐
100.00%买入
0.00%中性
0.00%落后大盘
0.00%卖出
目标价格预测
分析师预测PALI价格均价为7.00,最高价位7.00,最低价为7.00。
最高7.00
均价7.00
最低7.00
现价1.190
EPS
实际EPS
预期EPS
-2.72-1.91-1.10-0.29
Q4 2020
Q1 2021
Q2 2021
Q3 2021
Q4 2021
机构持股
总机构数: 44
机构持股: 84.16万
持股比例: 6.20%
总股本: 1,357.40万
类型机构数股数
增持
9
16.62万
建仓
2
10.51万
减持
2
2.05万
平仓
3
197.11万
  • 业绩
  • 资产分布
  • 分红历史
暂无数据
所属板块
生物技术和医学研究
-0.17%
制药与医学研究
-0.14%
高管信息
Chairman/Director
James Neal
President/Chief Operating Officer
Matthew Kalnik
Chief Executive Officer/Chief Financial Officer/Chief Accounting Officer
Dane Saglio
Chief Executive Officer/Director
Thomas Hallam
Director
Stephanie Diaz
Director
Robert Trenschel
Director
Don Williams
Independent Director
Cristina Csimma
Independent Director
Mary Gray
Independent Director
Binxian Wei
暂无数据
PALI 简况
Palisade Bio Inc(原名:Seneca Biopharma Inc)是一家生物制药公司。该公司专注于开发疗法,以帮助患有急性和慢性胃肠道问题的患者避免术后消化酶的损害。其候选产品LB1148是可用于III期的蛋白酶抑制剂,可减少腹部粘连并有助于在手术后恢复肠道功能。它致力于开发口服产品候选物以治疗因蛋白酶(肠道消化酶)逸出肠道而引起的疾病,包括外科疾病和炎症。LB1148是一种丝氨酸蛋白酶抑制剂的口服制剂,旨在中和手术期间从肠道释放的有效消化蛋白酶的活性。

微牛提供Palisade Bio Inc(NASDAQ-PALI)的股票价格、实时市场报价、专业分析师评级、深度图表和免费的PALI股票新闻,以帮助您做出投资决策。

模拟交易:模拟炒股免费实操交易技能。您可用虚拟资金在真实市场环境中零成本、零风险体验交易PALI股票基本功能。